Amid ongoing legal battles over coveted GLP-1 therapies, a drug vendor in Washington state is accused of running an ...
Novo Nordisk faces competition from Eli Lilly in new therapeutic areas. Read why I rate NONOF stock as a hold.
The U.S. Food and Drug Administration (FDA) is rethinking its decision to remove popular weight-loss and diabetes drugs from ...
To combat these alternative sellers, pharmaceutical company Eli Lilly began offering an alternative version of its brand-name ...
11don MSN
Danish biotech Zealand Pharma is targeting the “next generation” of weight loss drugs as competitors pile into a market ...
The agency agreed in court to allow compounding companies to continue producing copycat versions of Lilly’s fast-selling medicines while it reevaluates its recent decision to declare the drugs back in ...
Here is a look at Tuesday’s business headlines with Jane King, where she discusses Lilly suing over claims of copycat weight ...
When you're taking GLP-1 medications for weight loss, it's easy for nutrition to get overlooked because while semaglutide ...
Zepbound and Mounjaro, two medications from Eli Lilly and Company (NYSE:LLY), have been approved to treat obesity and type 2 diabetes, respectively, and are anticipated to bolster the company’s ...
The U.S. Food and Drug Administration, after intense public pressure and a lawsuit, is reconsidering its declaration barely two weeks ago that a shortage of the appetite-suppressing drugs Mounjaro ...
The Center for Human Nutrition at the U of A is conducting a research study to learn more about the effects of protein on body composition and wellbeing in people getting ready to take weight loss ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback